Here are five insights:
1. The company hopes to receive clearance to test its cell therapy drug in a clinical trial.
2. The therapy, BRTX-100, is intended to treat chronic lower back pain caused by degenerative disc disease.
3. BRTX-100 includes autologous cultured mesenchymal stem cells from a patient's bone marrow.
4. The product is designed for a non-surgical, intradiscal procedure performed in a physician's office.
More articles on spine:
Drs. Kern Singh, Hyun Bae & more: 5 spine surgeons & neurosurgeons recently receiving honors — Jan. 9, 2017
Are infections associated with analgesic steroid paste after spinal decompression? 5 key notes
3 spine surgeons in the headlines — Jan. 6, 2017